ACCESS-AD
Ensuring timely diagnosis and equitable treatment for Alzheimer’s disease across Europe
Alzheimer’s disease (AD) is a growing public health challenge in Europe’s ageing population. While Disease Modifying Therapies (DMTs) bring new therapeutic potential, fragmented care pathways, unequal diagnostic access, and healthcare limitations threaten their effectiveness and scalability. The Access AD Project is a collaborative initiative that exemplifies the public-private partnership model, bringing together government agencies and private sector organizations to address this unmet need by translating advanced diagnostics and monitoring approaches—such as blood-based and imaging biomarkers, digital and AI tools—into coordinated, equitable, and scalable care across real-world clinical settings in Europe. The project aims to ensure that every individual with AD can access timely, personalized, and cost-effective care, regardless of geography or socioeconomic status. ACCESS-AD builds on local, national, and EU-level efforts to create an integrated, pan-European framework for optimized AD care.
The project will achieve the following:
- establish robust coordination and governance to ensure efficient delivery and stakeholder alignment
- connect and expand fragmented clinical and research data through a shared platform, linking registries and initiatives across Europe
- reduce diagnostic access barriers by improving standardized imaging, blood-based, and digital biomarkers for clinical use
- develop AI-driven tools to support personalized treatment decisions
- generate harmonized real-world evidence on DMTs and emerging therapies
- assess health-economic, regulatory, and patient-reported impacts
- engage patients, professionals, and policymakers to ensure adoption and sustainability
Aligned with IHI Call 9.2, ACCESS-AD unites and engages diverse healthcare stakeholders and integrates needs and perspectives of individuals affected by dementia to deliver inclusive, connected, and personalized care centered around the AD patient. By translating innovation into real-world practice, the project will reduce inequalities, support health policy, and improve outcomes for AD patients across Europe.
Within the project, CERTH ITI’s BHV Group is responsible for the deployment of digital patient-monitoring tools. These digital health solutions will support tracking cognitive and functional decline by detecting adverse effects of DMTs, such as neurological changes or physiological shifts.
